Form 4: ANI Pharmaceuticals CEO Nikhil Lalwani Reports Stock Transaction
SEC Form 4 Filing
Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, reported a transaction involving the withholding of shares for tax purposes related to the vesting of restricted stock.
Summary
- On March 23, 2024, Nikhil Lalwani, the President & CEO of ANI Pharmaceuticals, reported a transaction.
- The transaction involved the withholding of 17,455 shares of common stock at a price of $69.58 per share for tax purposes.
- This was related to the vesting of 34,124 shares of restricted stock previously granted.
- Following the transaction, Lalwani beneficially owns 394,174 shares of ANI Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, and the transaction itself is neutral in sentiment.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a standard tax withholding procedure.
Key Dates
| Date | Description |
|---|---|
| 03/23/2024 | Date of the reported transaction (stock withholding for tax purposes). |
| 03/25/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.